Streetbeat News

Stock Prices

LVS

Over the past 15 years, Las Vegas Sands (NYSE:LVS) has produced an average annual return of 14.65%, outperforming the market. A $1000 investment in LVS 15 years ago would be worth $8,502.82 today. The company's current market capitalization stands at $34.09 billion.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 4:30 pm

SPSC

SPS Commerce (NASDAQ:SPSC) has delivered an impressive average annual return of 24.57% over the past 15 years, outperforming the market. A $100 investment in SPSC 15 years ago would be worth $2,700.22 today. The company currently holds a market capitalization of $6.82 billion.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 4:30 pm

DXCM

DexCom (NYSE:DXCM) has seen a 15.65% decrease in short interest since its last report, with 17.75 million shares sold short, representing 5.28% of its float. The average time to cover these short positions is 3.86 days. A decrease in short interest can indicate a more bullish sentiment among investors. DexCom's short interest is higher than its peer group average of 3.57%.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 4:30 pm

GIII

Wells Fargo analyst Ike Boruchow has maintained an Equal-Weight rating on G-III Apparel Group (NASDAQ:GIII) and increased the price target from $25 to $30.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 4:29 pm

DAL

Delta Air Lines' stock is trading higher as the company has reaffirmed its guidance for both the fourth quarter and the full year of 2023, indicating confidence in its financial outlook.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 4:24 pm

ALT

JNJ

LLY

NVO

PFE

RHHBY

Johnson & Johnson's CEO Joaquin Duato stated that the company is not planning to enter the weight-loss drug market due to existing competition, focusing instead on expanding in neurology and oncology. Eli Lilly, Novo Nordisk, and Roche Holdings are already significant players in the obesity treatment market. Roche recently acquired Carmot Therapeutics for $2.7 billion. Altimmune's stock rose after Phase 2 obesity trial results, while Pfizer's fell due to high discontinuation rates in a trial. JNJ shares dropped 1.11% recently.

Portfolio Pulse from Vandana Singh

December 06, 2023 | 4:23 pm

ODFL

Old Dominion Freight Line's stock is trading lower following the announcement of a year-over-year decline in their November revenues per day.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 4:22 pm

SSNT

SilverSun Technologies Inc (NASDAQ:SSNT) shares dropped 13.8% to $8.49 after a recent surge due to a $1 billion investment from Jacobs Private Equity II. Jacobs will become CEO and major shareholder, planning to split the business and pursue acquisitions in a new industry, alongside a rebranding effort. The company's 52-week range is $2.67 to $7.14.

Portfolio Pulse from Henry Khederian

December 06, 2023 | 4:22 pm

POWL

Powell Industries' stock price is trading lower following the release of their fourth-quarter financial results.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 4:21 pm

SIG

Wells Fargo analyst Ike Boruchow has maintained an Overweight rating on Signet Jewelers (NYSE:SIG) and increased the price target from $100 to $110.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 4:21 pm